These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31044147)

  • 1. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
    Nakahara J; Tomaske L; Kume K; Takata T; Kamada M; Deguchi K; Kufukihara K; Schneider R; Gold R; Ayzenberg I
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e559. PubMed ID: 31044147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
    Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
    BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.
    Mickeviciene D; Baltusiene A; Afanasjeva B; Afanasjevas D; Gleizniene R; Rastenyte D; Berger JR
    BMC Neurol; 2022 Aug; 22(1):306. PubMed ID: 35986243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Van Schependom J; Gielen J; Laton J; Nagels G
    Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
    Barritt AW; Das E; Morley N; Seymour M; Saha R; Vera J; Vundavalli S; Dizdarevic S; Nicholas R; Berger JR; Fisniku LK
    Mult Scler; 2023 Feb; 29(2):301-306. PubMed ID: 36451581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Berger JR; Cree BA; Greenberg B; Hemmer B; Ward BJ; Dong VM; Merschhemke M
    Neurology; 2018 May; 90(20):e1815-e1821. PubMed ID: 29669908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
    Cuascut FX; Alkabie S; Hutton GJ
    Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
    Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
    [No Abstract]   [Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
    J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
    Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
    BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
    Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.